To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)
Status:
RECRUITING
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines